Bliss GVS Pharma Limited — Others, 31-07-2025: Shareholders meeting

Bliss GVS Pharma held its 40th Annual General Meeting. Management detailed significant business expansions, including product diversification into international markets like the US, Canada, CIS, and the Middle East, with Sub-Saharan Africa remaining a key market. The company highlighted successful commercialization of US ANDA approvals and new product supplies to Canada/UK, alongside efforts to triple suppository manufacturing capacity. These strategic investments position the company for a new phase of growth. Shareholders approved the audited financial statements for FY25 and declared a final dividend of Re. 0.50 per equity share. Director re-appointments and auditor appointments were also approved.